Alzheimer’s drug shows promise in slowing cognitive decline
An experimental Alzheimer’s drug, called lecanemab, has successfully met its primary endpoints in a Phase III trial, which found it slows cognitive decline and improves daily activities.
Nearly 50 million people worldwide are living with Alzheimer’s, and as populations age, this number continues to increase. It is vital that we develop effective treatments; however, the Alzheimer’s treatment landscape is one littered with failed drugs. This may change with a new experimental drug, developed by Eisai (Tokyo, Japan) and Biogen (MA, USA), showing historically positive results in a large Phase III trial called CLARITY-AD.
